Myelodysplastic Syndrome

20
OKEWA Japheth Siome Elizabeth AdoyoRolex Maklago Kevin Okoth KIPKIRUI Nicholas Herold KipkiruiAduwa Clinton MARSA Subo Hassan Odoyo MikeLaura Kimondo KIPRONO DominicRosebella Chamoro Marcia Obondi

Transcript of Myelodysplastic Syndrome

Page 1: Myelodysplastic Syndrome

OKEWA Japheth Siome Elizabeth Adoyo Rolex MaklagoKevin OkothKIPKIRUI Nicholas Herold Kipkirui Aduwa ClintonMARSA Subo Hassan Odoyo Mike Laura KimondoKIPRONO Dominic Rosebella Chamoro Marcia Obondi

Page 2: Myelodysplastic Syndrome

Lecture Objectives

Introduction to MDS

Classification of MDS: FAB & WHO

Aetiology & Pathogenesis

Clinical features of MDS

Diagnosis

Management

Page 3: Myelodysplastic Syndrome

Introduction

Group of clonal disorders of multipotent

hemopoietic stem cells

Qualitative and quantitative

abnormality in all 3 myeloid lines.

Cytopenias develop Progress to AML, but death results before

this.

Page 4: Myelodysplastic Syndrome

Classification

FAB Classification WHO classification

Page 5: Myelodysplastic Syndrome

Modality of classification

RA- Dysplasia in RBC only

RCMD- Dysplasia in 2 or more myeloid lineage

RAEB- Blasts increase in blood or bone marrow

5q syndrome- Good prognosis

Unclassified- Unilineage dysplasia of myeloid or megakaryocytic lineage

• Poor prognosis

Page 6: Myelodysplastic Syndrome

Aetiology

Primary MDS• Major one• 30-50% cases are of

chromosomal abnormality• Exposure to low doses of

chemotherapy and organic chemicals

Secondary/Therapy related MDS• Long term cytotoxic chemo,

radiotherapy & Autologous transplant for lymphoma• Risk increases 4-10 years after Rx

with alkylating agents eg chlorambucil

Page 7: Myelodysplastic Syndrome

Pathogenesis

Inherited

Acquired

DNA Damage

Myeloid Stem Cell

Myelodysplastic Clone

Myelodysplastic Syndrome

AML

Increased Angiogenesis

Immune Damage

Increased Apoptosis

Abnormal marrow microenvironment

Secondary genetic and epigenetic

abnormalities

Page 8: Myelodysplastic Syndrome

Clinical Features

• 4/100000 incidence

• Discovered by chance• ½ of patients are over 70yrs and

< 25% are less than 50 years

• Symptoms of anemia, infection, easy bruising and bleeding• Splenomegaly uncommon unless

in CMML MDS

Page 9: Myelodysplastic Syndrome

I just

discover

ed that

you have

MDS

I didn't know that I have MDS

Page 10: Myelodysplastic Syndrome
Page 11: Myelodysplastic Syndrome

Diagnosis

Observe symptoms of bone marrow

failure

Splenomegaly in 10% of

CMMLBlood film

BM aspiration & Trephine

biopsy

Chromosome analysis

Page 12: Myelodysplastic Syndrome

Erythroid lineageBlood Bone marrow

Increased marrow cellularity

Multinucleate normoblasts

Ring sideroblastsHypocellular cells like in

aplastic anemiaFibrosisAbnormal chromatin

pattern

Hypochromic cells. Sometimes normoblasts

MacroovalocytesBasophilic

stiplingsreticulocytopenia

Page 13: Myelodysplastic Syndrome
Page 14: Myelodysplastic Syndrome

Myeloid (Blood)GranulocytopeniaHypogranular

neutrophilsPegler abnormality (bi-

lobed nuclei)Hypolobated neutrophil

nucleimyeloblasts

Page 15: Myelodysplastic Syndrome

Megakaryocytic

Blood• Agranular platelets• megakaryocytes

Marrow• Macro megakaryocytes• Micronulclear• Mononuclear• Megakaryocytes with separated

nuclei• Binuclear/polynuclear forms

Page 16: Myelodysplastic Syndrome

Cytogenetics

• Partial or total loss in chromosome 5/7 or trisomy 8• N-RAS oncogene mutation in 20 % of cases• FMS mutation in 15% of cases

Page 17: Myelodysplastic Syndrome

ManagementBefore management, consider: Age General fitness Severity of the condition Prognosis If the disease is stable or

has progressed

Page 18: Myelodysplastic Syndrome

Prognosis

Page 19: Myelodysplastic Syndrome

Complications of MDS

Anemia

Increased risk of bleeding

Recurrent infections

Increased risk of cancer (AML)

Ocular manifestations: Cotton wool spots, retinal hemorrhage, corneal ulceration

Page 20: Myelodysplastic Syndrome